Therapeutic Action
Antifungal
PDF page 145
Loading InternPractice…
Drug reference
Antifungal
PDF page 145
Cryptococcocal meningitis (induction phase), in combination with amphotericin B or fluconazole
PDF page 145
Administer with caution and monitor use in patients > 60 years or with renal impairment or haematological disorders. Reduce the dose by half (25 mg/kg 2 times daily) in patients with renal impairment. May cause: gastrointestinal disturbances, haematological disorders (leukopenia, thrombocytopenia, less frequently, agranulocytosis), increase in transaminase levels, allergic reactions sometimes severe; sometimes, confusion and halucinations. Monitor blood count and liver and renal function until the end of treatment. Pregnancy and breast-feeding: flucytosine is generally not recommended. It is teratogenic in animals and its safety in pregnant or lactating women has not been established. However, taking into account the severity of the disease, the potential benefit of treatment for the mother and in the absence of a safer alternative, it may be used despite the potential risks for the child.
PDF page 145
500 mg capsule and tablet
PDF page 145
Child over 1 week and adult: 25 mg/kg 4 times daily
PDF page 145
One week if in combination with amphotericin B 2 weeks if in combination with fluconazole
PDF page 145
For children, tablets may be crushed. Also comes in 250 mg capsule and tablet.
PDF pages 145, 146
– Below 25 °C
PDF page 146
25 mg/kg 4 times daily
PDF page 145